No abstract available.
Chimerism ; Hematopoietic Stem Cells

No abstract available.
Chimerism ; Thyroid Diseases ; Thyroid Gland

No abstract available.
Chimerism* ; Stem Cell Transplantation* ; Stem Cells*

No abstract available.
Bone Marrow* ; Chimerism* ; Hematologic Neoplasms* ; Recurrence*

Chimerism ; Graft vs Host Disease ; Liver Transplantation

The microchimerism is a status of the microcell or DNA of an individual in another one with genetic differences. Taking an overall view about the discovery and research of the microchimerism, it was found that although the study of the microchimerism emphasizes the formation, origin, distribution, type, relationship to disease and several other aspects, the objects of the study are always the microchimerism that obtained naturally. As it is known to all, the microchimerism can also be produced in some clinical treatment, such as in the transplant and transfusion, but compared with the microchimerism gained naturally, obviously, the study for the iatrogenic microchimerism formed in the treatment is not elaborate enough. The curative effect of micro transplantation, a new technique for leukemia treatment, is obvious, but its mechanism is unclear, whether that is related to microchimerism still needs further research. This review summarizes the study history and perspective of the microchimerism so as to provide some ideas for studying the action mechanism of microchimerism in micro transplantation.
Chimerism ; DNA ; genetics ; Humans ; Transplantation Chimera

Blood transfusion is a newly recognized cause of microchimerism, it seems to be common in severe traumatic injuries. In this review, the frequency, cause and prevention of transfusion-associated microchimerism (TA-MC), its current progress of knowledge and unanswered questions were summarized. In addition, the pregnancy-associated microchimerism and transplantation-associated microchimerism were discussed in this review.
Blood Donors ; Blood Transfusion ; Chimerism ; Humans ; Transplantation Chimera

The development of immunosuprressants has had a significant contribution to inhibition of acute allograft rejection. However, long-term graft survival has not been realized by immunosuppressants, probably because of their nonspecific suppression of T cell activity and nonimmune side effects. The ideal way to overcome the limitations of current immunosuppressants is to induce allograft-specific immune tolerance. Transplant immunologists are exerting their efforts in achieving transplantation tolerance using three different approaches; mixed hematopoietic chimerism, costimulatory blockade, and regulation by regulatory T cells. It is expected that transplantation tolerance will soon be established as a standard immunosuppressive regimen with little side effects in preventing and reversing allograft rejection.
Allografts* ; Chimerism ; Graft Survival ; Immune Tolerance* ; Immunosuppressive Agents ; T-Lymphocytes, Regulatory ; Transplantation Tolerance

The development of immunosuprressants has had a significant influence on inhibition of acute allograft rejection. However, long-term graft survival has not been achieved by immunosuppressants, probably because of their nonspecific suppression of T cell activity and nonimmune side effects. The ideal way to overcome the limitations of current immunosuppressants is to induce allograft-specific immune tolerance. Transplant immunologists are exerting their efforts in achieving transplantation tolerance using four different approaches; costimulatory blockade, mixed hematopoietic chimerism, T cell depletion, and regulation by regulatory T cells. It is expected that transplantation tolerance will soon be established as a standard immunosuppressive regimen with little side effects in preventing and reversing allograft rejection.
Allografts ; Chimerism ; Graft Survival ; Immune Tolerance ; Immunosuppressive Agents ; T-Lymphocytes, Regulatory ; Transplantation Tolerance*

BACKGROUND: ABO blood group discrepancy occurs when the results of red cell tests do not agree with those of the serum test. In order to select the proper blood units for transfusion, clarification of the cause of ABO discrepancies is essential. We analyzed the cases and recent actual transfusion experiences at Chonnam National University Hospital (CNUH). METHODS: In total, among pre-transfusion blood samples at CNUH between January 2012 and July 2013, 55 cases of ABO discrepancies were analyzed retrospectively. RESULTS: The discrepancy incidence was 0.14%. Problems with serum were the most common cause of ABO discrepancies, with 31 cases (56.4%), and extra serum reactivity due to cold allo-antibodies accounted for the highest frequency (n=7). There were three cases of non-specific aggregations caused by commercial RBC constituents and aggregation was not observed when a re-test was performed with other commercial RBCs or self-prepared human RBCs. Two of three cases with mix-field aggregations involved a pair of twins after in vitro fertilization - embryo transfer (IVF-ET). Among 55 patients, 20 were actually transfused, and all but four cases had weaker or identical RBC units and stronger or identical plasma units. CONCLUSION: There were newly revealed ABO discrepancies caused by non-specific aggregations of commercial RBCs and in twins after IVF-ET. In addition, investigation of actual transfusion experiences in patients with ABO blood group discrepancies would be helpful.
Chimerism ; Embryo Transfer ; Fertilization in Vitro ; Humans ; Incidence ; Jeollanam-do* ; Plasma ; Retrospective Studies ; Twins